Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR3 | P46089 | 2/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | PARP1 | P09874 | 2/20 | 0.42 |
| ▸ | ELANE | P08246 | 2/20 | 0.42 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10516378 | 0.98 | KDM4E (0.55) | GPR3KDM4ECYP2A6ALDH1A1CYP1A2 | |
| Perchlorate SCHEMBL3903406 | 0.91 | GPR3 (0.47) | GPR3KDM4ECYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL23028710 | 0.85 | KDM4E (0.57) | GPR3KDM4ECYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL27331612 | 0.83 | KDM4E (0.46) | GPR3KDM4ECYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL30857515 | 0.81 | KDM4E (0.61) | GPR3KDM4EALDH1A1CYP1A2PDPK1 | |
| SCHEMBL31555325 | 0.80 | KDM4E (0.50) | GPR3KDM4ECYP2A6ALDH1A1CYP1A2 | |
| SCHEMBL9038627 | 0.79 | KDM4E (0.59) | GPR3KDM4EALDH1A1CYP1A2PDPK1 | |
| SCHEMBL6590915 | 0.79 | KDM4E (0.59) | GPR3KDM4EALDH1A1CYP1A2PARP1 | |
| SCHEMBL27973182 | 0.79 | GPR3 (0.64) | GPR3KDM4EALDH1A1CYP1A2PDPK1 | |
| SCHEMBL10025808 | 0.78 | GPR3 (0.68) | GPR3KDM4EALDH1A1CYP1A2PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 107 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115260097-A | 5-methylphenanthridine compound and application thereof in preparing drug or probe for reducing or detecting thioredoxin reductase level | 兰州大学 | 2022-11-01 | — | — | CN | claimed |
| EP-3542801-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAP-RELATED DISEASES | Boehringer Ingelheim International GmbH (DE) | 2019-09-25 | — | — | EP | claimed |
| EP-3029040-B1 | METHOD FOR PRODUCING CHIRAL 8-(3-AMINO-PIPERIDIN-1-YL) -XANTHINES | BOEHRINGER INGELHEIM INT (DE) | 2019-04-03 | — | — | EP | claimed |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2016-05-19 | — | — | US | claimed |
| US-8883805-B2 | Process for the preparation of chiral 8-(3-aminopiperidin-1-yl)-xanthines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-11-11 | — | — | US | claimed |
| EP-1761517-B1 | NOVEL IMIDAZOLES AND TRIAZOLES, THE PRODUCTION THEREOF, AND THE USE OF THE SAME AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2014-09-24 | — | — | EP | claimed |
| EP-2287164-B9 | Process for the manufacture of chiral 8-(3-aminopiperidin-1-yl)-xanthines | BOEHRINGER INGELHEIM INT (DE) | 2014-06-11 | — | — | EP | claimed |
| EP-2287164-B1 | Process for the manufacture of chiral 8-(3-aminopiperidin-1-yl)-xanthines | BOEHRINGER INGELHEIM INT (DE) | 2014-01-22 | — | — | EP | claimed |
| US-20130178485-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-07-11 | — | — | US | claimed |
| EP-1797093-B1 | NOVEL 3-METHYL-7-BUTINYL-XANTHINES, PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS | BOEHRINGER INGELHEIM INT (DE) | 2012-05-30 | — | — | EP | claimed |
| US-7470716-B2 | Imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-30 | — | — | US | claimed |
| US-20080312243-A1 | IMIDAZOLES AND TRIAZOLES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | ECKHARDT MATTHIAS | 2008-12-18 | — | — | US | claimed |
| US-7432262-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-10-07 | — | — | US | claimed |
| US-7393847-B2 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGLEHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | claimed |
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | ECKHARDT MATTHIAS | 2007-06-21 | — | — | US | claimed |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-06-29 | — | — | US | claimed |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-04-13 | — | — | US | claimed |
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-03-16 | — | — | US | claimed |
| US-20060004074-A1 | New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2006-01-05 | — | — | US | claimed |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142383-A1 | Imidazopyridazinediones, Their Preparation And Their Use As Pharmaceutical Compositions | DPP4, DPP3, DPP7 | GPR3 1363/4885KDM4E 898/4885CYP2A6 349/4885 |
| US-20130178485-A1 | PROCESS FOR THE PREPARATION OF CHIRAL 8-(3-AMINOPIPERIDIN-1-YL)-XANTHINES | XDH, UGT1A8, CYP2C8 | GPR3 1112/4885KDM4E 1290/4885CYP2A6 205/4885 |
| US-20050203095-A1 | Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | GPR3 1330/4885KDM4E 904/4885CYP2A6 367/4885 |
| US-20060142310-A1 | for preventing or treating disorders connected with an increased DPP-IV activity, especially of diabetes mellitus type I or type II, prediabetes, or reduction of glucose tolerance; 1-[(4-methylquinazolin-2-yl)methyl]-3-methyl-7-(2-butin-1-yl)-8-(3-(R)-aminopiperidin-1-yl)-xanthine | DPP4, DPP7, DPP8 | GPR3 1359/4885KDM4E 772/4885CYP2A6 701/4885 |
| US-20060058323-A1 | New 8-(3-amino-piperidin-1-yl)-7-(but-2-ynyl)-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP8, DPP4, DPP7 | GPR3 1117/4885KDM4E 895/4885CYP2A6 758/4885 |
| US-20060004074-A1 | New imidazoles and triazoles, their preparation, and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | GPR3 746/4885KDM4E 1010/4885CYP2A6 753/4885 |
| US-20160136180-A1 | PURIN DERIVATIVES FOR USE IN THE TREATMENT OF FAB-RELATED DISEASES | PNP, ENTPD5, NUDT14 | GPR3 2903/4885KDM4E 3292/4885CYP2A6 4497/4885 |
| US-20080312243-A1 | IMIDAZOLES AND TRIAZOLES, THEIR PREPARATION, AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | GPR3 950/4885KDM4E 960/4885CYP2A6 642/4885 |
| US-20060079541-A1 | 3-methyl-7-butinyl-xanthines, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP7, DPP3 | GPR3 748/4885KDM4E 566/4885CYP2A6 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.